REG-Arix Bioscience PLC Result of Annual General Meeting 2022

Arix BioscienceAnnouncement

07/06/2022 16:45

============

   Arix Bioscience PLC (ARIX)
   Result of Annual General Meeting 2022

   07-Jun-2022 / 16:44 GMT/BST
   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ════════════════════════════════════════════════════════════════════════════

    

                               Arix Bioscience plc

                                         

                      Result of Annual General Meeting 2022

    

   LONDON, 7 June  2022: Arix Bioscience  plc (“Arix” or  the “Company”)  (LSE:
   ARIX), announces that  at its  Annual General Meeting  (the "Meeting")  duly
   convened and held today, all resolutions as set out on the notice of meeting
   were duly  passed by  way of  a poll.  Resolutions 1  to 11  were passed  as
   ordinary  resolutions.  Resolutions  12  to   15  were  passed  as   special
   resolutions.

    

   Full details  of  the poll  results  are set  out  below and  will  also  be
   available on the Company's  1 website.

    

                                       VOTES           TOTAL     % of   VOTES
   No  RESOLUTION  VOTES FOR    %     AGAINST    %     VOTES     ISC   WITHHELD
                                                                VOTED
       To receive
          the
       Directors'
       Report and
      the accounts
   1     of the    63,669,622 99.99%   5,609   0.01% 63,675,231 49.29%  10,853
      Company for
        the year
        ended 31
        December
          2021
       To approve
          the
   2   Directors'  63,589,770 99.90%  65,188   0.10% 63,654,958 49.28%  31,126
      Remuneration
         Policy
       To approve
          the
   3   Directors'  60,232,861 94.62% 3,422,747 5.38% 63,655,608 49.28%  30,476
      Remuneration
         Report
      To re-elect
       Peregrine
   4   Moncreiffe  60,068,424 94.35% 3,599,164 5.65% 63,667,588 49.29%  18,496
          as a
        Director
      To re-elect
   5    Maureen    59,600,160 93.61% 4,068,028 6.39% 63,668,188 49.29%  17,896
      O'Connell as
       a Director
      To re-elect
   6     Isaac     63,450,417 99.66%  217,771  0.34% 63,668,188 49.29%  17,896
      Kohlberg as
       a Director
      To re-elect
   7  Robert Lyne  63,451,455 99.66%  216,733  0.34% 63,668,188 49.29%  17,896
          as a
        Director
      To elect Sir
   8    Michael    60,231,844 94.60% 3,436,344 5.40% 63,668,188 49.29%  17,896
      Bunbury as a
        Director
       To appoint
   9   BDO LLP as  63,659,891 99.98%  12,947   0.02% 63,672,838 49.29%  13,246
      auditors of
      the Company
      To authorise
       the Audit
        and Risk
   10 Committee of 63,667,766 99.99%   4,772   0.01% 63,672,538 49.29%  13,546
      the Company
       to fix the
       auditor's
      remuneration
      To authorise
   11     the      63,632,590 99.94%  40,130   0.06% 63,672,720 49.29%  13,364
      Directors to
      allot shares
      Authority to
        disapply
   12  statutory   58,648,467 92.11% 5,021,253 7.89% 63,669,720 49.29%  16,364
      pre‐ emption
         rights
       Additional
      authority to
   13   disapply   58,653,953 92.12% 5,015,767 7.88% 63,669,720 49.29%  16,364
       statutory
      pre‐ emption
         rights
      To authorise
      the Company
   14 to purchase  63,648,630 99.96%  22,560   0.04% 63,671,190 49.29%  14,894
        its own
         shares
      Authority to
         call a
        general
        meeting,
       other than
   15  an annual   63,666,745 99.99%   8,786   0.01% 63,675,531 49.29%  10,553
        general
      meeting, on
        not less
        than 14
      clear days'
         notice

    

   In accordance with Listing Rule 9.6.2, copies of resolutions passed at the
   Meeting concerning items other than ordinary business will shortly be
   available for inspection on the National Storage Mechanism, which can be
   accessed at  2 https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

   The full text of the resolutions considered at the AGM are contained in the
   Notice of AGM, published on 12 May 2022, which is available on Arix investor
   relations  3 website.

                                       ENDS 

    

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

   ir 4 @arixbioscience.com

    

   Powerscourt Group

   Sarah MacLeod, Ibrahim Khalil, Nick Johnson

   +44 (0)20 7250 1446

    5 arix@powerscourt-group.com

    

   About Arix Bioscience plc

   Arix Bioscience plc is a global venture capital company focused on investing
   in breakthrough biotechnology companies around cutting-edge advances in life
   sciences.

    

   We collaborate  with  exceptional  entrepreneurs and  provide  the  capital,
   expertise, and global networks to help accelerate their ideas into important
   new treatments for patients. As a listed company, we are able to bring  this
   exciting growth  phase of  our industry  to a  broader range  of  investors.
    6 www.arixbioscience.com

    

    

   ════════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  RAG
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   166768
   EQS News ID:    1370371


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    7 fncls.ssp?fn=show_t_gif&application_id=1370371&application_name=news&site_id=refinitiv2

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=1a195bf7f89a604942a993d4071d25ee&application_id=1370371&site_id=refinitiv2&application_name=news
   2. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=ec6e3547bf15aa8f7a413f452253d987&application_id=1370371&site_id=refinitiv2&application_name=news
   3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=1a195bf7f89a604942a993d4071d25ee&application_id=1370371&site_id=refinitiv2&application_name=news
   4. mailto:charlotte@arixbioscience.com
   5. mailto:arix@powerscourt-group.com
   6. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1370371&site_id=refinitiv2&application_name=news


============